<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">

Publication:
Chrysin sensitizes glioblastoma cells and spheroids to temozolomide treatment by reducing EMT and stemness phenotypes, as well as targeting multidrug resistance proteins

Loading...
Thumbnail Image

Departments

Item type:Organizational Unit,

School / College / Institute

Item type:Organizational Unit,
SCHOOL OF MEDICINE
Upper Org Unit

Program

KU-Authors

Organization Authors

Co-Authors

Sengelen, Aslihan

Gursoy, Dudu Melek

Ogutcu, Irem

Kuvet, Ozge

Pekmez, Murat

Date

Language

Embargo Status

No

Journal Title

Journal ISSN

Volume Title

Alternative Title

Abstract

Background Glioblastoma (GB, grade-IV astrocytoma) is a highly aggressive brain tumor often resistant to treatment with temozolomide (TMZ) due to multidrug resistance (MDR). Researchers are investigating natural compounds, such as chrysin (CHR), with anti-cancer properties; however, its ability to overcome drug resistance remains unclear. This study aimed to evaluate the possible synergistic effects of CHR and TMZ on glioblastoma cells in 2D- and 3D-culture models.Methods Based on cytotoxicity (MTT test) and synergism analysis, U-87MG cells were treated with CHR (25 mu M) and TMZ (250 mu M), individually or combined, for 48 hours. Clonogenicity, migration, and invasion were assessed. Fluorescence staining was used to assess MtMP collapse, ER stress, autophagy, apoptosis, and target protein localization. Protein level alterations were measured using Western blotting, and network pharmacology was used to identify shared molecular targets. Antitumor effects were also assessed in 3D-tumor spheroids (mimics in vivo tumors), through viability and growth analyses.Results The combined treatment was more effective in reducing cell proliferation than either agent alone, in a dose- and time-dependent manner. CHR increased TMZ cytotoxicity by promoting mitochondrial dysfunction, ER stress, autophagy, and apoptosis, and further decreased motility, clonogenicity, EMT status, and stem-like traits. Co-treatment also suppressed the TMZ-induced upregulation and nuclear translocation of P-glycoprotein (identified as a key CHR target through network pharmacology analysis) and NF-kappa B-p65, as well as reduced the expression of stress proteins (Hsp60, Hsp70, Hsp90) and MRP1. In 3D spheroid models, co-treatments significantly impaired growth and viability.Conclusion These findings suggest that CHR may be a promising adjuvant to TMZ therapy, providing novel insights into overcoming chemoresistance in GB treatment.

Source

Publisher

Frontiers

Citation

item.page.haspartof

Source

Frontiers in Pharmacology

item.page.ispartofseries

item.page.edition

DOI

10.3389/fphar.2025.1643186

item.page.datauri

item.page.link

Rights

CC BY (Attribution)

Copyrights Note

Creative Commons license

Except where otherwise noted, this item's license is described as CC BY (Attribution)

Endorsement

Review

Supplemented By

Referenced By

Related Patent

Related Goal

Google Scholar
Scholar'da Ara ↗
Altmetric
Dimensions
PlumX Metrikleri
BIP! Indicators